1

Large-scale genome-wide association study to determine the genetic underpinnings of female genital tract polyps

- 3 **Running title:** GWAS of female genital tract polyps
- 4 Amruta D. S. Pathare^{1,3†*}, Natàlia Pujol-Gualdo^{2†}, Valentina Rukins², Jelisaveta Džigurski²,
- 5 Maire Peters^{1,3}, Estonian Biobank Research Team, Reedik Mägi², Andres Salumets^{1,3,4}, Merli
- 6 Saare^{1,3}, Triin Laisk²
- 7 1 Competence Centre on Health Technologies, Tartu, Estonia
- 8 2 Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia
- 9 3 Department of Obstetrics and Gynaecology, Institute of Clinical Medicine, University of
- 10 Tartu, Tartu, Estonia
- 4 Division of Obstetrics and Gynaecology, Department of Clinical Science, Intervention and
 Technology (CLINTEC), Karolinska Institute and Karolinska University Hospital, Stockholm,
 Sweden
- *Corresponding author: Amruta D. S. Pathare, <u>amruta.pathare@ut.ee</u> ORCID No: 00000002-5608-2370
- 16
- 17

^{*} Norrea unisorre counsiderisinate these first that cash borsees have like by pgar dealers a jointo fills to deal to guide clinical practice.

18 Abstract

19 STUDY QUESTION

- 20 Can a large-scale genome-wide association study (GWAS) meta-analysis identify the genomic
- 21 risk loci and associated candidate genes for female genital tract (FGT) polyps, provide insights
- 22 into the mechanism underlying their development, and inform potential overlap with other
- 23 traits, including endometrial cancer?

24 SUMMARY ANSWER

GWAS meta-analysis of FGT polyps highlighted the potentially shared mechanisms betweenpolyp development and cancerous processes.

27 WHAT IS KNOWN ALREADY

Small-scale candidate gene studies have focused on biological processes such as estrogen stimulation and inflammation to clarify the biology behind FGT polyps. However, the exact mechanism for the development of polyps is still elusive. At the same time, a genome-wide approach, which has become the gold standard in complex disease genetics, has never been used to uncover the genetics of the FGT polyps.

33 STUDY DESIGN, SIZE, DURATION

We performed a genome wide association study (GWAS) meta-analysis including a total of 25,100 women with FGT polyps (International Classification of Disease, ICD-10 diagnosis code N84) and 207,193 female controls (without N84 code) of European ancestry from the FinnGen study (11,092 cases and 94,394 controls) and the Estonian Biobank (EstBB, 14,008 cases and 112,799 controls).

3

39 PARTICIPANTS/MATERIALS, SETTING, METHODS

A meta-analysis and functional annotation of GWAS signals were performed to identify and
prioritise genes in associated loci. To determine associations with other phenotypes, we
performed a look-up of associated variants across multiple traits and health conditions, a genetic
correlation analysis, and a phenome-wide association study (PheWAS) with ICD10 diagnosis
codes.

45 MAIN RESULTS AND THE ROLE OF CHANCE

Our GWAS meta-analysis revealed ten significant ($P < 5 \ge 10^{-8}$) genomic risk loci. Two signals, 46 $rs2277339 (P = 7.6 \times 10^{-10})$ and $rs1265005 (P = 1.1 \times 10^{-9})$ (in linkage disequilibrium (LD) with 47 rs805698 $r^2 = 0.75$), are exonic missense variants in *PRIM1*, and *COL17A1* genes, respectively. 48 49 Based on the literature, these genes may play a role in cellular proliferation. Several of the identified genomic loci had previously been linked to endometrial cancer and/or uterine 50 fibroids. Thus, highlighting the potentially shared mechanisms underlying tissue overgrowth 51 52 and cancerous processes, which may be relevant to the development of polyps. Genetic correlation analysis revealed a negative correlation between sex hormone-binding globulin 53 (SHBG) and the risk of FGT polyps (rg = -0.21, se = 0.04, $P = 2.9 \times 10^{-6}$), and on the phenotypic 54 level (PheWAS), the strongest associations were observed with endometriosis, leiomyoma of 55 the uterus and excessive, frequent and irregular menstruation. 56

57 LARGE SCALE DATA

58 The complete GWAS summary statistics will be made available after publication through the
59 GWAS Catalogue (https://www.ebi.ac.uk/gwas/).

60 LIMITATIONS, REASONS FOR CAUTION

4

In this study, we focused broadly on polyps of FGT and did not differentiate between the polyp subtypes. The prevalence of FGT polyps led us to assume that most women included in the study had endometrial polyps. Further study on the expression profile of FGT polyps could complement the GWAS study to substantiate the functional importance of the identified variants.

66 WIDER IMPLICATIONS OF THE FINDINGS

67 The study findings have the potential to significantly enhance our understanding of the genetic 68 mechanisms involved, paving the way for future functional follow-up, which in turn could 69 improve the diagnosis, risk assessment, and targeted treatment options, since surgery is the only 70 line of treatment available for diagnosed polyps.

71 TRIAL REGISTRATION NUMBER:

72 Not applicable

Key words: Genome-wide association study, Female genital tract polyps, Endometrial polyps,
Benign disorders, cell proliferation, *PRIM1*, *COL17A1*.

75 Introduction

Polyps of the female genital tract (FGT) are generally benign tissue overgrowths found
in both reproductive-aged and postmenopausal women. While the prevalence of polyps can be
as high as 50%, most women are asymptomatic. Hence, polyps are usually detected incidentally
during routine ultrasound examinations, diagnostic hysteroscopy for other gynaecological
disorders, or infertility treatment among women of reproductive age (Hinckley and Milki, 2004;
Fatemi *et al.*, 2010; Karayalcin *et al.*, 2010; Bettocchi *et al.*, 2011). However, the occurrence
of polyps is age-dependent, with a higher prevalence among postmenopausal women compared

5

to premenopausal women (Dreisler *et al.*, 2009). Despite the asymptomatic and benign nature
of FGT polyps, for some women, they can negatively impact the daily quality of life by causing
abnormal vaginal bleeding and infertility.

86 Endometrial polyps (EPs) are the most common type of FGT polyps, with a prevalence ranging from 7.8% to 50% (Dreisler et al., 2009; de Azevedo et al., 2016; Tanos et al., 2017). 87 88 In contrast, endocervical polyps occur only in 2% to 5% of cases, whereas vaginal polyps are rarer (Tanos et al., 2017); therefore, limited evidence is available about their biology and 89 90 clinical implications. Some known risk factors for the development of EPs are advanced age, 91 hypertension, diabetes, obesity, hyperoestrogenism, administration of hormone replacement 92 therapy (HRT), and tamoxifen (Vitale et al., 2021; Vieira et al., 2022). Nevertheless, the exact 93 pathogenesis of FGT polyps remains unclear. Histologically, EPs are characterised by large, 94 thickened blood vessels with fibrous stroma and irregularly shaped glandular spaces (Tanos et 95 al., 2017). Moreover, EPs can be associated with concomitant intrauterine pathologies like endometrial hyperplasia, adenomyosis, endometriosis and chronic endometritis (Annan et al., 96 97 2012; Raz et al., 2021). Despite the benign nature of EPs, around 3.5% of cases progress into carcinoma (Lee et al., 2010; Sasaki et al., 2018; Uglietti et al., 2019). At the same time, the 98 99 extent of biological mechanisms and pathways shared between EPs and carcinoma, as well as 100 unique molecular characteristics of each condition remain unclear.

Very little is known about the heritability and genetic background of FGT polyps.
Genetic factors, including chromosomal translocations in 6p21-22, 12q13-15, or 7q22 regions,
may contribute to polypoid morphology (Dal Cin *et al.*, 1995; Nijkang *et al.*, 2019; Vieira *et al.*, 2022), and genetic disorders like Lynch or Cowden syndrome have been reported to be
accountable for the development of EPs (Vieira *et al.*, 2022). However, a recent study by Sahoo
et al. did not confirm the presence of chromosomal rearrangements in endometrial polyps
(Sahoo *et al.*, 2022).

6

108 Thus, the confirmed pathophysiology for the development of FGT polyps is still 109 unknown. However, it can be assumed that the development and mechanism of polyps are 110 multifactorial and can also depend on genetic predisposition. Thus far, the proposed genetic 111 mechanisms are primarily based on small candidate gene studies and are inconclusive (Altaner 112 et al., 2006; Pal et al., 2008; Banas et al., 2018; Doria et al., 2018; Takeda et al., 2019). Studies 113 in other complex diseases have shown that genome-wide association studies (GWAS) can provide valuable insight into disease biology (Claussnitzer et al., 2016), but as far as we are 114 115 aware, no large-scale GWAS have been published for FGT polyps. Therefore, we performed a 116 GWAS meta-analysis to identify the genetic variants associated with FGT polyps, followed by 117 numerous post-GWAS analyses to understand the shared and unique genetic underpinnings of 118 FGT polyps and endometrial cancer. Ultimately, this knowledge can highlight potential clinical 119 avenues for appropriate diagnosis and management of FGT polyps.

120 Materials and methods

121 Ethical approval

All Estonian Biobank (EstBB) participants have signed a broad informed consent form, and analyses were carried out under ethical approvals 1.1-12/624 and 1.1-12/2733 from the Estonian Committee on Bioethics and Human Research (Estonian Ministry of Social Affairs) and data release application 6-7/GI/630 from the EstBB. For the FinnGen study, we used only publicly available GWAS summary statistics without individual-level data and thus, a separate ethics approval was not needed.

128 Study cohorts

Our analyses included a total of 25,100 women with polyps of the FGT (International
Classification of Disease, ICD-10 diagnosis code N84) and 207,193 female controls (without

7

the N84 code) of European ancestry from two studies: summary level statistics from the
FinnGen R7 data release (11,092 cases and 94,394 controls) and individual-level data from the
EstBB (14,008 cases and 112,799 controls). In FinnGen, cases were defined using the ICD-10
code N84 or corresponding ICD-9 (6210, 6227, 6237, 6246) and ICD-8 (62520) codes. Similar
to EstBB, controls were defined as women who did not have the abovementioned disease codes.

136 To increase study power, we did not distinguish between different types of FGT polyp 137 location in our phenotype definition. However, according to the FinnGen Risteys browser 138 (https://r7.risteys.finngen.fi/phenocode/N14 POLYPFEMGEN), 20% of FGT polyp cases were also cases for phenotype "Uterine polyps", while in the EstBB data, 70.5 % of N84 cases 139 140 had a diagnosis for uterine polyps (as defined by the presence of the ICD-10 code N84.0). This 141 most likely reflects differences in the source of phenotype information - FinnGen phenotype 142 definitions mostly use hospital records and thus involve more severe cases, while the EstBB 143 also uses primary care records.

144 Cohort-level analyses

145 The EstBB is a population-based biobank including more than 200,000 individuals 146 (approximately 135,000 of them women) representing 20% of the Estonian adult population. 147 Information on ICD codes is obtained via regular linking with the National Health Insurance 148 Fund and other relevant databases. Individuals with ICD-10 code N84 (mean age at recruitment 149 49.2 years, standard deviation 12.1) were categorised as cases having been diagnosed with 150 polyps of the genital tract, and all female biobank participants without the diagnosis were 151 considered as controls (mean age at recruitment 44.3 years, sd 16.6). The genotyping procedure 152 for EstBB has been described previously (Koel et al., 2023; Laisk et al., 2021; Pujol-Gualdo et 153 al., 2022). Briefly, Illumina GSAv1.0, GSAv2.0, and GSAv2.0_EST arrays were used for the 154 genotyping of biobank participants at the Core Genotyping Lab of the Institute of Genomics,

8

University of Tartu. Individuals with a call-rate less than 95% and sex mismatch between 155 156 phenotypic and chromosomal data were excluded from the analysis. Before imputation, genotyped variants were filtered by applying criteria of call rate < 95%, Hardy-Weinberg 157 equilibrium $P < 10^{-4}$ (for autosomal variants only), and minor allele frequency < 1%. Eagle 158 159 v2.3 software was used for pre-phasing, and Beagle was used for imputation. The populationspecific imputation reference of 2297 whole genome sequencing samples was used. Association 160 161 analysis was performed using REGENIE v2.2.4 with year of birth and 10 principal components 162 as covariates in step I, and variants with a minor allele count < 5 were excluded by default. In 163 downstream association analysis, poorly imputed variants with an INFO score < 0.4 were excluded. 164

For FinnGen, GWAS summary statistics from the R7 data release were used, and therefore, individual-level data was not available. The summary statistics were obtained from https://www.finngen.fi/en/access_results, whereas the FinnGen cohort and the genotyping/data analysis details have been previously described in Kurki et al. (Kurki *et al.*, 2023). To summarise, age, 10 principal components, and genotyping batch were used in REGENIE v2.0.2 analysis as covariates, and for FinnGen summary statistics, variants with a minor allele count > 5 and imputation INFO score > 0.6 were included.

172 GWAS meta-analysis

A meta-analysis using fixed-effects inverse variance weighting with genomic control was performed with the GWAMA v2.1 tool. The genome-wide significance level was set to $P < 5 \times 10^{-8}$. The genomic inflation factors (lambda) for the individual study summary statistics were 1.046 (EstBB) and 1.045 (FinnGen). Variants present in both cohorts (n = 12,363,169) were included in downstream analyses.

178 Annotation of GWAS signals

9

To annotate the GWAS signals and prioritise potential biologically relevant genes atassociated loci, we adopted the following approach.

181 First, we used the Functional Mapping and Annotation of Genome-Wide Association Studies (FUMA GWAS) platform v1.5.2 to identify genetic association loci. FUMA is an online 182 183 platform designed for the annotation, prioritisation, and interpretation of GWAS results that 184 uses data from multiple databases to annotate GWAS signals (Watanabe et al., 2017). In the 185 first step of this analysis, independent significant variants, lead signals and genomic risk loci 186 were defined. Independent significant variants (IndSigSNPs) were defined as variants that were genome-wide significant (P $< 5 \times 10^{-8}$) and had a pairwise LD r² < 0.6, according to the 1000G 187 188 EUR reference panel. From this subset, lead variants were derived. Finally, risk loci were defined from independent significant SNPs by merging LD blocks if they are less apart than r^2 189 190 < 0.6. Thus, a genomic risk locus can contain several lead SNPs and/or independent significant 191 SNPs, depending on the size of the locus and the LD structure. Thereafter, potential significant 192 candidate SNPs (GWAS meta-analysis P > 0.05) were determined to be in LD with any of the IndSigSNPs ($r^2 \ge 0.6$) within a 1Mb window and had a MAF of $\ge 1\%$. These candidate SNPs 193 194 were subjected to further annotation using multiple databases such as Annotate Variation 195 (ANNOVAR) (Wang et al., 2010), RegulomeDB scores (ranging from 1 to 7, where lower 196 score indicates greater evidence for having regulatory function) (Boyle et al., 2012), and 197 Combined Annotation-Dependent Depletion (CADD) (a continuous score showing how 198 deleterious the SNP is to protein structure/function; scores >12.37 indicate potential 199 pathogenicity) (Kircher et al., 2014), 15 chromatin states from the Roadmap Epigenomics 200 Project (ENCODE Project Consortium, 2012; Roadmap Epigenomics Consortium et al., 2015), 201 expression quantitative trait loci (eQTL) data (genotype-tissue expression (GTEx) v6 and v7) 202 (GTEx Consortium, 2013) and 3D chromatin interactions from HI-C experiments of 21 203 tissues/cell types (Schmitt et al., 2016). This process provides information on the location,

10

functional impact, and potential regulatory effects of detected SNPs. For eQTL annotations, we
focused on tissues similar to uterine/vaginal tissue (GTEx Consortium, 2020).

206 Using the lead signal identified by FUMA, we performed a look-up in the Open Targets genetics database (Ghoussaini et al., 2021). This database combines several layers of evidence 207 208 across a wide range of cell types and tissues to generate an aggregate 'variant to gene' (V2G) score. The V2G score provides identification and correlation of likely causal variants and genes 209 210 to prioritise the potential functional genes associated with the identified variants. V2G score 211 aggregates several parameters like distance from the canonical transcript start site, eQTLs and 212 protein QTLs (pQTLs) datasets, datasets for chromatin interactions and conformation, 213 molecular phenotypes, and in silico functional predictions (using the Variant Effect Predictor 214 or VEP score).

215 Briefly, we prioritised genes in the identified loci by selecting three genes having the 216 highest V2G score. Then we additionally identified those loci where the GWAS signal includes 217 a missense variant using annotation data from FUMA. To provide additional support for 218 prioritisation and further explore regulatory effects, we looked at eQTL associations according 219 to FUMA annotations, and if none were reported, we looked at potential chromatin interactions 220 as these may also indicate regulatory effects. To gain insight into endometrial-specific eQTLs, 221 we queried the candidate SNPs defined by FUMA in the endometrial eQTL database (Fung et 222 al., 2018).

223 Gene-based testing

Analysis by Multi-marker Analysis of GenoMic Annotation (MAGMA) v1.6 (de Leeuw *et al.*, 2015), with the default settings in FUMA (Watanabe *et al.*, 2017), was used to perform gene-based association analysis to complement the single variant analyses. Gene-based analysis enables to detect the joint effect of multiple genetic variants and can thus increase the power to detect associations. Briefly, variants located in the gene body were assigned to protein-coding

11

genes (n = 18,895; Ensembl build 85), and the SNP P-values were merged into a gene test statistic using the SNP-wise mean model (de Leeuw *et al.*, 2015). The level of genome-wide significance was set at $0.05/18,895 = 2.6 \times 10^{-6}$, taking into account the number of tested genes.

232 Genetic associations with other traits:

During the FUMA functional mapping, candidate SNPs were linked with the GWAS catalogue (https://www.ebi.ac.uk/gwas/, GWAS Catalogue e0_r2022-11-29, FUMA v1.5.1) to explore the association of genetic variants with previously published GWAS of different phenotypic traits.

237 Genetic correlation analysis

To estimate the genetic correlations between our FGT polyps meta-analysis and 1,335 other traits, we utilised the LD Score Regression method implemented in the Complex Traits Genetics Virtual Lab (CTG-VL) (https://genoma.io/) and 3 additional endometrial cancer traits available in the GWAS catalogue (accession codes GCST006464, GCST006465 and GCST006466) (Bulik-Sullivan *et al.*, 2015). Statistical significance was determined by applying a multiple testing correction (FDR < 5%) using the p.adjust function in R v3.6.3.

244 Associations with other phenotypic traits

245 To determine the associations between ICD-10 diagnosis main codes and the N84 246 diagnosis of polyps in the FGT, we conducted an analysis using individual level data from the 247 EstBB. Logistic regression was used to test the associations between N84 and other ICD-10 248 codes while controlling for age at recruitment and 10 genetic principal components to account 249 for population stratification and avoid false associations due to ancestry/regional differences 250 between cases and controls. Age was included as a covariate to account for incomplete 251 electronic diagnosis data for older participants in the biobank. Our analysis was limited to the 252 diagnosis main codes along with all the subcodes to increase the power of the data. Statistically

12

significant associations were determined by applying Bonferroni correction (2000 tested ICD main codes, corrected P threshold of 2.5 x 10⁻⁵). Odds ratios (ORs) were calculated by the logistic regression method and represented as adjusted ORs. The resulted associations were filtered to remove the diagnoses related to exogenous factors (such as injuries, poisoning, accidents, assaults, etc. in the S, T, U, V, W, X, and Y subchapters) and the PheWAS library (https://github.com/PheWAS/PheWAS) was used to visualise the results. All analyses were performed using R v4.1.3

260 In the FinnGen data, we did not have access to the individual level data, but using the 261 Risteys portal (https://r7.risteys.finngen.fi/phenocode/N14 POLYPFEMGEN), we explored the results of the survival analysis evaluating associations between FGT polyps and other 262 263 selected phenotypes. A detailed description of the survival analysis can be found in the Risteys 264 documentation (https://r7.risteys.finngen.fi/documentation), but briefly, this type of analysis 265 tests the association between an exposure endpoint and an outcome endpoint. For example, in 266 the context of FGT polyps, what is the association between a diagnosis of FGT polyp (exposure endpoint) and endometrial carcinoma (outcome endpoint). 267

268 Results

269 Summary of GWAS

GWAS of a total of 25,100 women with polyps of the FGT and 207,193 female controls revealed ten significant (P < 5 x 10⁻⁸) genomic risk loci and 23 independent signals (Fig. 1, Table 1). The strongest signal, rs1702136 (P = 2.17 x 10⁻¹⁹), was observed on chromosome 3, which is an intronic variant of the *EEFSEC* gene. The majority of the significant signals (91.3%) were either intronic or intergenic variants, whereas two signals, rs2277339 (P = 7.57 x 10⁻¹⁰) and rs1265005 (P = 1.09 x 10⁻⁹, in LD with rs805698, r² = 0.75) on chromosomes 12 and 10, respectively, were exonic missense variants.

13

277

Table 1. Summary statistics of significant genomic risk loci with lead SNP and 278

independent significant SNP. 279

chr:pos:A1:A2	rsID of	P-value	OR (95%)	IndSigSNP	Effect	Heter
	Lead SNP		CI)	S	Allele	ogene
	(effect				frequency	ity p-
	allele)				(Est/Fin)	value
3:128118711:A:	rs1702136	2.17 x 10 ⁻	0.90 (0.88-	rs1702136	0.75/0.75	0.99
G	(G)	19	0.92)	rs3732402		
				rs4857866		
				rs7650365		
				rs2999051		
				rs13095166		
				rs74924715		
				rs1735527		
8:116869477:C:	rs800578	4.91 x 10 ⁻	1.08 (1.05-	rs800578	0.24/0.26	0.90
Т	(T)	11	1.10)	rs2736213		
4:95731394:A:G	rs2865375	4.36 x 10 ⁻	0.93 (0.92-	rs2865375	0.54/0.52	0.45
	(A)	10	0.95)	rs10033997		
12:57146069:G:	rs2277339(7.57 x 10 ⁻	1.10 (1.06-	rs2277339	0.87/0.86	0.37
Т	T)	10	1.13)			
10:105585753:C	rs19309775	7.59 x 10 ⁻	0.83 (0.78-	rs19309775	0.97/0.95	0.92
:T	3 (C)	10	0.88)	3		
				rs17116149		
				rs7911816		
				rs11360949		
				6		
				rs1265005		
1:61592380:A:G	rs12751005	1.09 x 10 ⁻⁹	1.06 (1.04-	rs12751005	0.68/0.67	0.90
	(A)		1.09)			
13:41869725:A:	rs77478686	8.21 x 10 ⁻⁹	1.18 (1.12-	rs77478686	0.97/0.95	0.67
G	(G)		1.26)			


14


5:142162633:A:	rs7728894	1.84 x 10 ⁻⁸	0.93 (0.91-	rs7728894	0.73/0.75	0.60
G	(G)		0.96)			
5:1285974:A:C	rs7705526	2.33 x 10 ⁻⁸	0.94 (0.92-	rs7705526	0.68/0.68	0.45
	(C)		0.96)			
19:8786624:A:G	rs2967684	2.72 x 10 ⁻⁸	0.93 (0.90-	rs2967684	0.81/0.76	0.40
	(G)		0.95)			

280 *Alleles presented in alphabetical order

281 IndSigSNPs: Independent significant SNP

282





296 Functional annotation of associated variants and gene prioritisation

We performed a look-up in the Open Targets Genetics database to evaluate the 297 functional association of identified genomic loci and potentially mapped genes reflected by the 298

15

- 299 V2G score. We additionally highlighted those loci where the GWAS signal includes a missense
- 300 variant using annotation data from FUMA (Table 2). Full details of gene prioritisation together
- 301 with supporting evidence from FUMA eQTL and chromatin interaction mapping, can be found
- in Supplementary Table 1.

303 Table 2. Summary of gene prioritisation results

Locus	Lead variant	Highest V2G score	Exonic variants	Biological evidence
3:128118711: A:G	rs1702136	EEFSEC RPN1 DNAJB8	NA	<i>EEFSEC</i> potential endometrial cancer susceptibility gene (Kho <i>et al.</i> , 2021)
8:116869477: C:T	rs800578	TRPS1	NA	Potential tumour suppressor candidate in endometrial cancer (Liang <i>et al.</i> , 2012)
4:95731394:A: G	rs2865375	BMPR1B PDLIM5 HPGDS	NA	<i>BMPR1B</i> is associated with female infertility. <i>BMPR1B-AS1</i> facilitates endometrial cancer cell proliferation (Lai <i>et</i> <i>al.</i> , 2022). <i>BmprIB</i> mutant mice exhibit a failure in endometrial gland formation (Yi <i>et</i> <i>al.</i> , 2001)
12:57146069: G:T	rs2277339	PRIM1 STAT6 HSD17B6	PRIM1	Cell proliferation, DNA replication
10:105585753: C:T	rs193097753	STN1 SH3PXD2A SLK	COL17A1	Cellular migration, cellular differentiation, extracellular matrix organisation

1:61592380:A: G	rs12751005	NFIA	NA	<i>NFIA</i> is involved in cellular growth and proliferation, tumour morphology. The gene is expressed in endometrial tissue (Humaidan <i>et al.</i> , 2012)
13:41869725: A:G	rs77478686	NAA16 MTRF1 KBTBD7	NA	Differential expression of <i>NAA16</i> is associated with the pathogenesis of endometriosis (She <i>et</i> <i>al.</i> , 2022)
5:142162633: A:G	rs7728894	ARHGAP26 FGF1 SPRY4	NA	ARHGAP26 promotes ovarian cancer cell invasion and migration (Chen <i>et al.</i> , 2019)
5:1285974:A: C	rs7705526	TERT CLPTM1L SLC6A18	NA	<i>TERT-CLPTM1L</i> locus is a known susceptibility region for cancerous processes
19:8786624:A: G	rs2967684	ACTL9 NFILZ ADAMTS10	NA	ACTL9 locus associated with endometriosis (Rahmioglu <i>et al.</i> , 2023)

304

305 Based on coding variants in our GWAS signals, we were able to prioritise PRIM1 and COL17A1 306 in loci on chromosomes 12 and 10, respectively. PRIM1 is a DNA primase involved in the 307 initiation of DNA replication by synthesising RNA primers for Okazaki fragments during 308 discontinuous DNA replication (Shiratori et al., 1995). rs2277339 is also a cis-eQTL for PRIM1 in endometrial tissue, which further supports PRIM1 as a candidate gene in this locus. 309

17

COL17A1, on the other hand, is primarily involved in cellular migration, cellular differentiation,
and extracellular matrix organisation (Jones *et al.*, 2020). While these genes have not yet been
directly associated with FGT polyps, their biological functions, particularly those related to
cellular proliferation, highlight their potential involvement in the development of polyps.

Several of the prioritised candidate genes had previously been associated with (endometrial) cancer - *EEFSEC*, *TRPS1*, *TERT/CLPTM1L*, one could be directly linked with endometrial biology (*BMPR1B*), and for the remaining, their biological significance in FGT polyps remains unclear.

318 Gene-based associations of female genital tract polyps:

319 To combine the joint effect of multiple genetic variants and increase the power to detect 320 associations, we performed a MAGMA gene-based test implemented in FUMA. Eight genes 321 were identified which passed the recommended threshold for significance (P = 2.6×10^{-6} , Bonferroni correction for association testing of 18,895 protein-coding genes): EEFSEC, TERT, 322 323 RUVBL1, BMPR1B, TRPS1, COL17A1, BET1L, WBP4 (Supplementary Figure 1, 324 Supplementary Table 2). Majority of these associations mirror the genes prioritised in the single 325 variant analysis, while the *BET1L* locus was not genome-wide significant in the single variant 326 analysis and is thus novel. Previously, BET1L has been associated with endometrial cancer (Bateman et al., 2017) and uterine fibroids (Cha et al., 2011; Edwards et al., 2013; Liu et al., 327 328 2018).


329 GWAS catalogue look-up

We searched the GWAS catalogue for associations between previously published phenotypic traits and candidate SNPs identified by the FUMA tool to gain additional insight into their potential biological roles (Fig. 2, Supplementary Table 3). Based on the GWAS catalogue look-up, the *TERT-CLPTM1L* (rs7705526) locus was clearly associated with cancers,

18

334	including the development of reproductive cancers such as ovarian cancer and prostate cancer.
335	Potential involvement in cancerous processes was also observed for the EEFSEC locus
336	(rs4857866), which was associated with prostate cancer and also nominally with endometrial
337	cancer (P < 1 x 10^{-6}). Several identified signals were related to reproductive traits, including
338	menarche (rs2277339-PRIM1), menopause (rs2277339-PRIM1), gestational age (rs4857866-
339	EEFSEC) and uterine fibroids (rs2277339-PRIM1, rs193097753-COL17A1, rs17116149-
340	COL17A1). The rs193097753 signal was additionally associated with the known risk factors
341	for the development of FGT polyps, such as type 2 diabetes ($P < 5 \times 10^{-8}$) and waist-to-hip ratio
342	$(P < 2 \times 10^{-11})$, further substantiating its functional significance.

343





345

Figure. 2: GWAS catalogue look-up showing associations between genetic variants associated with female genital tract polyps and other phenotypes. The figure highlights the genome-wide significant ($P < 5 \ge 10^{-8}$) association between FGT polyps genetic risk factors (individual significant SNPs) and previously published phenotypic traits and disorders.

350 Look-up of variants associated with endometrial cancer

351 Since there is some overlap between FGT polyp genetic risk loci and those known to be 352 associated with (endometrial) cancer, we conducted a look-up of variants associated with 353 endometrial cancer (O'Mara *et al.*, 2018) in our GWAS data. Of the 19 SNPs queried, seven

20


were nominally significant (P < 0.05) (rs9668337-*SSPN*, rs1740828-*SOX4*, rs17601876-*CYP19A1*, rs882380-*SNX11*, rs3184504-*SH2B3*, rs1129506-*EVI2A*, rs11263761-*HNF1B*) in the FGT polyp analysis as well (Supplementary Table 4). When querying the 10 lead variants associated with FGT polyp in the endometrial cancer summary statistics, we observed that three were nominally significant (P < 0.05) in the endometrial cancer and also in the endometrial cancer with endometrioid histology studies (rs1702136-*EEFSEC*, rs2865375-*BMPR1B*, rs7705526-*TERT*).


361 Genetic correlation between FGT polyps and other traits

362 We conducted pairwise genetic correlation (rg) analyses to examine the relationship 363 between polyps of the FGT and 1,335 different traits obtained from the Complex Traits 364 Genetics Virtual Lab (CTG-VL, https://genoma.io/) and 3 additional endometrial cancer traits 365 available in the GWAS catalogue (accession codes GCST006464, GCST006465 and 366 GCST006466). After running the analysis and correcting for multiple testing, we identified a 367 total of 11 significant (FDR < 0.05) genetic correlations. Selected genetic correlations between 368 polyps and various phenotypic categories such as anthropometrics, cardiovascular diseases, 369 genitourinary traits, mood disorders, sex hormones and surgical procedures are displayed in Fig. 3, full results in Supplementary Table 5. As expected, a positive genetic correlation was 370 371 observed with genitourinary traits and hysterectomy, emphasising that polyps are commonly 372 occurring incidental findings in gynaecological disorders. Furthermore, sex hormone-binding 373 globulin (SHBG) was negatively correlated with the risk of FGT polyps. We were not able to 374 detect a significant genetic correlation between FGT polyps and estradiol level or BMI, known 375 risk factors of FGT polyps, in our dataset. FGT polyps showed weak correlation with two of 376 the three endometrial cancer phenotypes tested (endometrial cancer and endometrial cancer -377 endometrioid histology, both rg 0.25-0.27, se 0.12-0.13), but these associations were only nominally significant (P = 0.03) and did not pass multiple testing correction threshold. 378

21







382 The plot displays selected genetic correlations between female genital tract polyps and traits from various phenotypic categories such as anthropometrics, cardiovascular traits, 383 genitourinary traits, mood disorders, sex hormones and surgical procedures that are colour-384 coded. Significant associations after FDR multiple correction are shown in the lower panel, 385 386 while the upper panel shows selected traits of interest that do not pass the multiple testing 387 correction. The centre dot marks the estimated genetic correlation (rg) value, and error bars 388 indicate 95% confidence limits. The dotted red line indicates no genetic correlation.

389 Associations between polyps of FGT and other diagnosis codes

390 Additionally, to evaluate other phenotypes' association with FGT polyps, we performed a phenome-wide phenotype association analysis using the EstBB data for disease codes. All 391 239 phenotypic associations with a $P < 2.5 \times 10^{-5}$ (corresponding to a Bonferroni-corrected 392 393 threshold of 0.05/2020) are shown in Supplementary Table 6. The most significant association 394 of FGT polyps related to other phenotypes were: i) leiomyoma of uterus (D25), which are

22

395 uterine fibroids known to often occur together with EPs (Kınay et al., 2016); ii) endometriosis 396 (N80), which has been correlated with a high prevalence of endometrial polyps; iii) excessive, frequent and irregular menstruation (N92) which is one of the classical symptoms of EPs, and; 397 398 iv) other noninflammatory disorders of uterus except cervix (N85) (Fig. 4). Moreover, women 399 with a diagnosis for FGT polyps had significantly more diagnoses for benign neoplasms in 400 several tissues, such as the uterus (D26), ovary (D27), unspecified female genital organs (D28) 401 and D39) and skin (D23) as well as malignant neoplasms of the uterus (C54) and skin (C44). 402 In our analysis, nasal polyps (J33) and K62 (which includes anal/rectal polyps) were also 403 nominally significant, which supports the idea of some systemic tissue overgrowth in epithelial 404 tissues similar to endometrial polyps harbouring glandular and luminal epithelium.

405 For the highlighted associations, we queried the FinnGen Risteys R7 portal to see if we 406 observe similar associations in the Finnish data. While the analysis in the Estonian data does 407 not consider which diagnosis in the tested pair comes first, the FinnGen data survival analysis 408 tests the association in both directions. Uterine leiomyoma, endometriosis, other benign 409 neoplasm of uterus, benign neoplasm of ovary, malignant neoplasm of uterus, and carcinoma 410 in situ of endometrium were significantly associated with FGT polyps in the survival analysis 411 in FinnGen data, (Supplementary Table 7) both if the diagnosis occurred before, or after the 412 FGT polyp diagnosis.

413 The results of phenotypic associations of FGT polyps are in concordance with the observed 414 genetic associations and point to the fact that benign and cancerous processes share some 415 mechanisms (such as cellular proliferation) on a genetic level.

416

417




Figure 4: Association of Polyps of female genital tract (N84) with other phenotypes. 427

Each triangle in the plot corresponds to one ICD10 main code, and different colours represent 428 different diagnosis categories. The direction of the triangle represents the direction of effect and 429 430 upward-pointing triangles show increased significance of diagnosis code in female genital tract polyps. The red line indicates the Bonferroni corrected threshold for statistical significance. 431

432 Discussion

433 Gynaecological polyps are a common diagnosis in women, with potential negative implications for women's reproductive health and well-being. We conducted the first large-434 435 scale GWAS meta-analysis to study the genetic underpinnings of FGT polyps and their association with other phenotypic traits from two European ancestry biobanks. The analysis 436 437 revealed ten genomic risk loci, of which two (rs2277339 and rs193097753) tagged exonic 438 missense variants suggestive of plausible functional importance in the development of polyps. 439 Furthermore, several of the identified genetic risk loci have previously been associated with (endometrial) cancer and/or uterine fibroids. Genetic correlation analysis additionally showed 440 441 negative correlation with SHBG levels, but no statistically significant genome-wide correlation

24

with endometrial cancer. PheWAS analysis showed an increased prevalence of endometriosis,
irregular and excessive menstruation, uterine fibroids and neoplasms of the uterus and other
tissues in women with FGT polyps.

445 Even though most EPs are benign, there is still a certain level of risk these polyps may 446 progress to malignant transformation (Antunes et al., 2007; Lenci et al., 2014). According to a 447 systematic review and meta-analysis, 2.7%-3.6% of EPs can be considered malignant, with 448 significant heterogeneity in prevalence among pre- and postmenopausal women (Lee et al., 449 2010; Sasaki et al., 2018; Uglietti et al., 2019). While we saw no statistically significant genetic 450 correlation between FGT polyps and endometrial cancer, several of the mapped genetic risk 451 loci/prioritised genes (rs1702136-EEFSEC, rs800578-TRPS1, rs2865375-BMPR1B, and 452 rs7705526-TERT-CLPTM1L) have previously been associated with cancer either in GWAS or 453 functional studies (Liang et al., 2012; Wu et al., 2014; Kho et al., 2021; Dos Santos et al., 454 2022), most likely reflecting the fact that both benign and malignant tissue overgrowths may utilise the same cellular mechanisms to some extent. This is supported by the results of the 455 456 associated diagnoses analysis where women with a diagnosis of FGT polyp also have more 457 diagnoses related to benign and malignant neoplasms of the uterus, ovary, and skin. While the 458 associations with reproductive tract neoplasms may arise due to incidental findings during 459 diagnostic procedures, it cannot be ruled out that some women have a genetic predisposition to 460 tissue overgrowth that may manifest in either benign or malignant neoplasms in certain tissues. Apart from a few small-scale reports (Unler et al., 2016), there are no relevant studies 461 462 evaluating the prevalence of different neoplasms among women with FGT polyps, therefore, 463 our observations need to be confirmed and further evaluated in future studies.

We further saw significant associations of FGT polyps with uterine leiomyoma and endometriosis. Though the cellular composition, characteristics, and mechanism of origin of uterine fibroids and endometrial polyps differ from each other, they can occur concurrently due

25

to common risk factors like advanced age, obesity, and hormonal dysregulation (Kınay *et al.*,
2016; Pavone *et al.*, 2018). Further, increased prevalence of endometriosis among women with
FGT polyps emphasises the reported evidence of a higher prevalence of endometrial polyps in
endometriosis patients (Shen *et al.*, 2011; Zhang *et al.*, 2018; Lin *et al.*, 2020; Peters *et al.*,
2022).

472 Our genetic correlation analysis showed a significant negative correlation between 473 SHBG levels and the risk of FGT polyps. In females, testosterone and oestrogen levels are 474 regulated through their binding to SHBG, which helps maintain hormonal balance in the bloodstream. Lower levels of SHBG can result in elevated levels of free testosterone and free 475 476 oestrogen. As EPs are oestrogen dependent, lower SHBG may directly stimulate EP development. Moreover, the expression of aromatase 450 enzyme in the EPs, converts free 477 478 testosterone into oestrogen, further augments the stimulation of polyps' development (Filho et 479 al., 2007). Thus, our study's finding of the negative correlation of SHBG in FGT polyps 480 concords with this mechanism. Unexpectedly, our analysis did not reveal a genetic correlation 481 between oestradiol and EPs. The discrepancy between circulating plasma levels and localized 482 endometrial levels of oestradiol may underlie the lack of this correlation. In the literature, serum 483 levels of oestradiol were shown to be significantly lower (five times) than the endometrial oestradiol concentration in the proliferative phase (Huhtinen et al., 2012). The same trend was 484 observed in women with abnormal uterine bleeding and hyperplasia (Cortés-Gallegos et al., 485 1975). Given that abnormal bleeding and hyperplasia are important symptoms of endometrial 486 487 polyps, it suggests that localised oestradiol may play a more crucial role in EP development. 488 Additionally, a study reported no significant difference in circulating oestradiol concentration 489 among women with and without endometrial polyps (Cortés-Gallegos et al., 1975), which 490 further supports our finding. This can also explain the lack of correlation of FGT polyps with

26

BMI to some extent, as higher BMI is often associated with increased circulating oestradiollevels.

493 To understand how genetic variation impacts trait susceptibility, it is important to link 494 associated genetic variants with specific genes and mechanisms. We employed a diverse range 495 of data layers to map potential candidate genes for the identified genomic loci. Among others, 496 *PRIM1* (rs2277339) and *COL17A1* (rs193097753) were prioritised since the GWAS signals 497 tagged coding variants in these genes. In the literature, neither of these genes has been directly 498 correlated with FGT development. The PRIM1 gene is a key regulator of DNA replication 499 during cellular proliferation process. It has been shown that the PRIM1 expression was 500 upregulated in breast tumour tissues compared to healthy tissues, and its inhibition led to 501 tumour cell growth regression (Lee *et al.*, 2019). Furthermore, the *PRIM1*-induced tumour cell 502 growth is stimulated by oestrogen through activation of the oestrogen receptor (ER) (Lee et al., 503 2019). As per one of the postulated hypotheses, polyp development is related to oestrogen 504 stimulation with predominantly increased ER alpha (ER-alpha) and decreased progesterone 505 receptors (PRs) A and B in the glandular epithelium. On the other hand, in the stromal cells of 506 polyps, lower concentrations of ER and PR hinder the decidualization process, preventing them 507 from shedding off during menstruation (Mittal et al., 1996; Peng et al., 2009; Nijkang et al., 508 2019). Since the PRIM1 gene signalling is oestrogen-associated, this can provide important 509 insights into the probable functional mechanisms underlying the development of polyps. The 510 COL17A1 gene is closely associated with epithelial tumour progression and invasiveness (Jones 511 et al., 2020), suggesting that a shared biological mechanism related to epithelial cell 512 proliferation could be associated with the development of EPs. However, further functional 513 assays on PRIM1 and COL17A1 genes are needed to confirm these associations.

514 While our study is a large-scale study, it had certain limitations. The cohort from 515 Estonian and Finnish biobanks encompasses women with all kinds of reproductive polyps, and

27

our phenotype definition did not differentiate between the types/location of polyps to increase 516 517 study sample size power. However, considering the overall occurrence of polyps in the general 518 population, endometrial polyps would be more prevalent than the other types. A complete 519 understanding of the transcriptome profile of endometrial polyps is still lacking, resulting in 520 knowledge gaps regarding the interplay between genomic loci and the regulation of gene 521 expression. By addressing these knowledge gaps, we can gain valuable insights into the genetic factors and gene expression patterns that contribute to the pathogenesis of endometrial polyps 522 523 and potentially identify novel therapeutic targets for their management.

In conclusion, the first GWAS meta-analysis of FGT polyps highlights and clarifies the genetic mechanisms shared between EP development (tissue overgrowth) and cancerous processes. Furthermore, an analysis of associated diagnoses showed that women diagnosed with EPs have an increased prevalence of other diagnoses, such as endometriosis, uterine fibroids and both benign and malignant neoplasms, which could have implications for patient management and counselling.

530 **Supplementary data:** Supplementary data are available at Human reproduction online.

Data availability: FinnGen cohort level summary statistics can be accessed as described here:
<u>https://www.finngen.fi/en/access_results</u>. Protocol for accessing the Estonian Biobank data is
described here: <u>https://genomics.ut.ee/en/content/estonian-biobank</u>. GWAS meta-analysis
summary statistics will be made available via the GWAS Catalogue (data upload pending).

Author's roles: Authors A.D.S.P., N.P.G, A.S., M.P and T.L. participated in the conception of
the study, data analysis, and interpretation of the data, and writing the manuscript. V.R., J.D.,
and R.M. contributed to data analysis and interpretation. T.L., M.S., M.P., V.R., J.D. and A.S.
critically reviewed and provided feedback on each version of the manuscript and all the authors
approved the final version. The EstBB Research Team provided the EstBB genotype and
phenotype data.

28

541	Acknowledgements: We want to acknowledge the participants of the Estonian Biobank and
542	the participants and investigators of the FinnGen study. We also acknowledge the Estonian
543	Biobank Research team members Andres Metspalu, Tonu Esko, Mari Nelis, Georgi Hudjashov,
544	and Lili Milani.

545 Funding: N.P.G. was supported by MATER Marie Sklodowska-Curie which received funding 546 from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 813707. T.L. was supported by the Estonian Research Council grant PSG776. 547 548 This study was funded by European Union through the European Regional Development Fund 549 Project No. 2014-2020.4.01.15-0012 GENTRANSMED. Computations were performed in the 550 High-Performance Computing Center of University of Tartu. The study was also supported by the Estonian Research Council (grant no. PRG1076 and MOBJD1056) and Horizon 2020 551 552 innovation grant (ERIN, grant no. EU952516).

553 **Conflict of interest:** All the authors declared no conflict of interest.

554

555 **References:**

- Altaner S, Gucer F, Tokatli F, Guresci S, Ozdemir C, Puyan FO, Kutlu K. Expression of Bcl-2
 and Ki-67 in tamoxifen-associated endometrial polyps: comparison with
 postmenopausal polyps. *Onkologie* 2006;**29**:376–380.
- Annan JJ, Aquilina J, Ball E. The management of endometrial polyps in the 21st century. *The Obstetrician & Gynaecologist* 2012;14:33–38.
- Antunes A, Costa-Paiva L, Arthuso M, Costa JV, Pinto-Neto AM. Endometrial polyps in preand postmenopausal women: factors associated with malignancy. *Maturitas*2007;**57**:415–421.

- Azevedo JM da R de, Azevedo LM da R de, Freitas F, Wender MCO. Endometrial polyps:
 when to resect? *Arch Gynecol Obstet* 2016;**293**:639–643.
- Banas T, Pitynski K, Mikos M, Cielecka-Kuszyk J. Endometrial Polyps and Benign
 Endometrial Hyperplasia Have Increased Prevalence of DNA Fragmentation Factors 40
- and 45 (DFF40 and DFF45) Together With the Antiapoptotic B-Cell Lymphoma (Bcl-
- 570 2) Protein Compared With Normal Human Endometria. *Int J Gynecol Pathol*571 2018;**37**:431–440.
- Bateman NW, Dubil EA, Wang G, Hood BL, Oliver JM, Litzi TA, Gist GD, Mitchell DA,
 Blanton B, Phippen NT, *et al.* Race-specific molecular alterations correlate with
 differential outcomes for black and white endometrioid endometrial cancer patients. *Cancer* 2017;**123**:4004–4012.
- 576 Bettocchi S, Achilarre M, Ceci O, Luigi S. Fertility-Enhancing Hysteroscopic Surgery. *Semin* 577 *Reprod Med* 2011;29:075–082.
- 578 Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, Karczewski KJ, Park
 579 J, Hitz BC, Weng S, *et al.* Annotation of functional variation in personal genomes using
- 580 RegulomeDB. *Genome Res* 2012;**22**:1790–1797.
- 581 Cha P-C, Takahashi A, Hosono N, Low S-K, Kamatani N, Kubo M, Nakamura Y. A genome582 wide association study identifies three loci associated with susceptibility to uterine
 583 fibroids. *Nat Genet* 2011;43:447–450.
- Chen X, Chen S, Li Y, Gao Y, Huang S, Li H, Zhu Y. SMURF1-mediated ubiquitination of
 ARHGAP26 promotes ovarian cancer cell invasion and migration. *Exp Mol Med*2019;**51**:1–12.
- 587 Dal Cin P, Vanni R, Marras S, Moerman P, Kools P, Andria M, Valdes E, Deprest J, Van de
 588 Ven W, Van den Berghe H. Four cytogenetic subgroups can be identified in endometrial
 589 polyps. *Cancer Res* 1995;55:1565–1568.

- Doria PLS, Moscovitz T, Tcherniakovsky M, Fernandes CE, Pompei LM, Wajman M,
 Nimwegen AV, Haimovich S. Association of IGF-1 CA(n) and IGFBP3 rs2854746
 Polymorphisms with Endometrial Polyp Risk. *Biomed Res Int* 2018;2018:8704346.
- 593 Dos Santos GA, Viana NI, Pimenta R, Camargo JA de, Guimaraes VR, Romão P, Candido P,
- 594 Ghazarian V, Reis ST, Leite KRM, et al. Pan-cancer analysis reveals that CTC1-STN1-
- 595 TEN1 (CST) complex may have a key position in oncology. *Cancer Genet* 2022;262–
 596 263:80–90.
- 597 Dreisler E, Stampe Sorensen S, Ibsen PH, Lose G. Prevalence of endometrial polyps and
 598 abnormal uterine bleeding in a Danish population aged 20-74 years. *Ultrasound Obstet* 599 *Gynecol* 2009;**33**:102–108.
- Edwards TL, Hartmann KE, Velez Edwards DR. Variants in BET1L and TNRC6B associate
 with increasing fibroid volume and fibroid type among European Americans. *Hum Genet* 2013;132:1361–1369.
- ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human
 genome. *Nature* 2012;489:57–74.
- 605 Fatemi HM, Kasius JC, Timmermans A, Disseldorp J van, Fauser BC, Devroey P, Broekmans
- FJ. Prevalence of unsuspected uterine cavity abnormalities diagnosed by office
 hysteroscopy prior to in vitro fertilization. *Hum Reprod* 2010;25:1959–1965.
- Filho AMB de B, Barbosa IC, Maia H, Genes CC, Coutinho EM. Effects of subdermal implants
 of estradiol and testosterone on the endometrium of postmenopausal women. *Gynecol Endocrinol* 2007;23:511–517.
- Fung JN, Mortlock S, Girling JE, Holdsworth-Carson SJ, Teh WT, Zhu Z, Lukowski SW,
 McKinnon BD, McRae A, Yang J, *et al.* Genetic regulation of disease risk and
 endometrial gene expression highlights potential target genes for endometriosis and
 polycystic ovarian syndrome. *Sci Rep* 2018;8:11424.

- 615 Ghoussaini M, Mountjoy E, Carmona M, Peat G, Schmidt EM, Hercules A, Fumis L, Miranda
- 616 A, Carvalho-Silva D, Buniello A, *et al.* Open Targets Genetics: systematic identification
- 617 of trait-associated genes using large-scale genetics and functional genomics. *Nucleic*
- 618 *Acids Res* 2021;**49**:D1311–D1320.
- 619 GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* 2013;45:580–
 620 585.
- Hinckley MD, Milki AA. 1000 office-based hysteroscopies prior to in vitro fertilization:
 feasibility and findings. *JSLS* 2004;8:103–107.
- 623 Humaidan P, Van Vaerenbergh I, Bourgain C, Alsbjerg B, Blockeel C, Schuit F, Van Lommel
- L, Devroey P, Fatemi H. Endometrial gene expression in the early luteal phase is
 impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH
 antagonist co-treated IVF cycles. *Hum Reprod* 2012;27:3259–3272.
- Jones VA, Patel PM, Gibson FT, Cordova A, Amber KT. The Role of Collagen XVII in Cancer:
 Squamous Cell Carcinoma and Beyond. *Front Oncol* 2020;10:352.
- Karayalcin R, Ozcan S, Moraloglu O, Ozyer S, Mollamahmutoglu L, Batioglu S. Results of
 2500 office-based diagnostic hysteroscopies before IVF. *Reprod Biomed Online*2010;20:689–693.
- 632 Kho PF, Wang X, Cuéllar-Partida G, Dörk T, Goode EL, Lambrechts D, Scott RJ, Spurdle AB,
- 633 O'Mara TA, Glubb DM. Multi-tissue transcriptome-wide association study identifies
 634 eight candidate genes and tissue-specific gene expression underlying endometrial
 635 cancer susceptibility. *Commun Biol* 2021;4:1211.
- Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for
 estimating the relative pathogenicity of human genetic variants. *Nat Genet*2014;46:310–315.

- Kınay T, Öztürk Başarır Z, Fırtına Tuncer S, Akpınar F, Kayıkçıoğlu F, Koç S. Prevalence of
 endometrial polyps coexisting with uterine fibroids and associated factors. *Turk J Obstet Gynecol* 2016;**13**:31–36.
- Koel M, Võsa U, Jõeloo M, Läll K, Gualdo NP, Laivuori H, Lemmelä S; Estonian Biobank
 Research Team; FinnGen; Daly M, *et al.* GWAS meta-analyses clarify the genetics of
 cervical phenotypes and inform risk stratification for cervical cancer. Hum Mol Genet.
 2023,32:2103-2116.
- Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, Reeve MP, Laivuori
 H, Aavikko M, Kaunisto MA, *et al.* FinnGen provides genetic insights from a wellphenotyped isolated population. *Nature* 2023;613:508–518.
- Lai T, Qiu H, Si L, Zhen Y, Chu D, Guo R. Long noncoding RNA BMPR1B-AS1 facilitates
 endometrial cancer cell proliferation and metastasis by sponging miR-7-2-3p to
 modulate the DCLK1/Akt/NF-κB pathway. *Cell Cycle* 2022;21:1599–1618.
- Laisk T, Lepamets M, Koel M, Abner E, Estonian Biobank Research Team, Mägi R. Genomewide association study identifies five risk loci for pernicious anemia. *Nat Commun*2021;12:3761.
- Lee SC, Kaunitz AM, Sanchez-Ramos L, Rhatigan RM. The oncogenic potential of endometrial
 polyps: a systematic review and meta-analysis. *Obstet Gynecol* 2010;**116**:1197–1205.
- 657 Lee W-H, Chen L-C, Lee C-J, Huang C-C, Ho Y-S, Yang P-S, Ho C-T, Chang H-L, Lin I-H,
- 658 Chang H-W, *et al.* DNA primase polypeptide 1 (PRIM1) involves in estrogen-induced
 659 breast cancer formation through activation of the G2/M cell cycle checkpoint. *Int J*660 *Cancer* 2019;**144**:615–630.
- 661 Leeuw CA de, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of
 662 GWAS data. *PLoS Comput Biol* 2015;11:e1004219.

- 663 Lenci MA, Nascimento VAL do, Grandini AB, Fahmy WM, Depes D de B, Baracat FF, Lopes
- RGC. Premalignant and malignant lesions in endometrial polyps in patients undergoing
 hysteroscopic polypectomy. *Einstein (Sao Paulo)* 2014;12:16–21.
- Liang H, Cheung LWT, Li J, Ju Z, Yu S, Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, *et al.* Whole-exome sequencing combined with functional genomics reveals novel
- 668 candidate driver cancer genes in endometrial cancer. *Genome Res* 2012;**22**:2120–2129.
- Lin S, Xie X, Guo Y, Zhang H, Liu C, Yi J, Su Y, Deng Q, Zhu W. Clinical characteristics and
 pregnancy outcomes of infertile patients with endometriosis and endometrial polyps: A
 retrospective cohort study. *Taiwan J Obstet Gynecol* 2020;**59**:916–921.
- Liu B, Wang T, Jiang J, Li M, Ma W, Wu H, Zhou Q. Association of BET1L and TNRC6B
 with uterine leiomyoma risk and its relevant clinical features in Han Chinese population. *Sci Rep* 2018;8:7401.
- Mittal K, Schwartz L, Goswami S, Demopoulos R. Estrogen and progesterone receptor
 expression in endometrial polyps. *Int J Gynecol Pathol* 1996;15:345–348.
- Nichols CA, Gibson WJ, Brown MS, Kosmicki JA, Busanovich JP, Wei H, Urbanski LM,
 Curimjee N, Berger AC, Gao GF, *et al.* Loss of heterozygosity of essential genes
 represents a widespread class of potential cancer vulnerabilities. *Nat Commun*2020;11:2517.
- Nijkang NP, Anderson L, Markham R, Manconi F. Endometrial polyps: Pathogenesis, sequelae
 and treatment. *SAGE Open Med* 2019;**7**:2050312119848247.
- 683 O'Mara TA, Glubb DM, Amant F, Annibali D, Ashton K, Attia J, Auer PL, Beckmann MW,
- Black A, Bolla MK, *et al.* Identification of nine new susceptibility loci for endometrial
 cancer. *Nat Commun* 2018;**9**:3166.
- Pal L, Niklaus AL, Kim M, Pollack S, Santoro N. Heterogeneity in endometrial expression of
 aromatase in polyp-bearing uteri. *Hum Reprod* 2008;23:80–84.

- Pavone D, Clemenza S, Sorbi F, Fambrini M, Petraglia F. Epidemiology and Risk Factors of
 Uterine Fibroids. *Best Pract Res Clin Obstet Gynaecol* 2018;46:3–11.
- 690 Peng X, Li T, Xia E, Xia C, Liu Y, Yu D. A comparison of oestrogen receptor and progesterone
- 691 receptor expression in endometrial polyps and endometrium of premenopausal women.
- 692 *J Obstet Gynaecol* 2009;**29**:340–346.
- Peters M, Mikeltadze I, Karro H, Saare M, Estonian Biobank Research Team, Salumets A,
 Mägi R, Laisk T. Endometriosis and irritable bowel syndrome: similarities and
 differences in the spectrum of comorbidities. *Hum Reprod* 2022;**37**:2186–2196.
- Pujol-Gualdo N, Läll K, Lepamets M, Estonian Biobank Research Team, Rossi H-R, Arffman
 RK, Piltonen TT, Mägi R, Laisk T. Advancing our understanding of genetic risk factors
 and potential personalized strategies for pelvic organ prolapse. *Nat Commun*2022;13:3584.
- Rahmioglu N, Mortlock S, Ghiasi M, Møller PL, Stefansdottir L, Galarneau G, Turman C,
 Danning R, Law MH, Sapkota Y, *et al.* The genetic basis of endometriosis and
 comorbidity with other pain and inflammatory conditions. *Nat Genet* 2023;55:423–436.
- Raz N, Feinmesser L, Moore O, Haimovich S. Endometrial polyps: diagnosis and treatment
 options a review of literature. *Minim Invasive Ther Allied Technol* 2021;**30**:278–287.
- 705 Roadmap Epigenomics Consortium, Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A,
- Heravi-Moussavi A, Kheradpour P, Zhang Z, Wang J, *et al.* Integrative analysis of 111
 reference human epigenomes. *Nature* 2015;**518**:317–330.
- 708 Sahoo SS, Aguilar M, Xu Y, Lucas E, Miller V, Chen H, Zheng W, Cuevas IC, Li H-D, Hitrys
- D, *et al.* Endometrial polyps are non-neoplastic but harbor epithelial mutations in
 endometrial cancer drivers at low allelic frequencies. *Mod Pathol* 2022;35:1702–1712.

Sasaki LMP, Andrade KRC, Figueiredo ACMG, Wanderley M da S, Pereira MG. Factors

711

712	Associated with Malignancy in Hysteroscopically Resected Endometrial Polyps: A
713	Systematic Review and Meta-Analysis. J Minim Invasive Gynecol 2018;25:777–785.
714	Schmitt AD, Hu M, Jung I, Xu Z, Qiu Y, Tan CL, Li Y, Lin S, Lin Y, Barr CL, et al. A
715	Compendium of Chromatin Contact Maps Reveals Spatially Active Regions in the
716	Human Genome. Cell Rep 2016;17:2042–2059.
717	She J, Su D, Diao R, Wang L. A Joint Model of Random Forest and Artificial Neural Network
718	for the Diagnosis of Endometriosis. Front Genet 2022;13:848116.
719	Shen L, Wang Q, Huang W, Wang Q, Yuan Q, Huang Y, Lei H. High prevalence of endometrial
720	polyps in endometriosis-associated infertility. Fertil Steril 2011;95:2722-2724.e1.
721	Shiratori A, Okumura K, Nogami M, Taguchi H, Onozaki T, Inoue T, Ando T, Shibata T, Izumi
722	M, Miyazawa H. Assignment of the 49-kDa (PRIM1) and 58-kDa (PRIM2A and
723	PRIM2B) subunit genes of the human DNA primase to chromosome bands 1q44 and
724	6p11.1-p12. Genomics 1995;28:350-353.
725	Takeda T, Banno K, Kobayashi Y, Adachi M, Yanokura M, Tominaga E, Kosaki K, Aoki D.
726	Mutations of RAS genes in endometrial polyps. Oncol Rep 2019;42:2303–2308.
727	Tanos V, Berry KE, Seikkula J, Abi Raad E, Stavroulis A, Sleiman Z, Campo R, Gordts S. The
728	management of polyps in female reproductive organs. Int J Surg 2017;43:7–16.
729	Uglietti A, Buggio L, Farella M, Chiaffarino F, Dridi D, Vercellini P, Parazzini F. The risk of
730	malignancy in uterine polyps: A systematic review and meta-analysis. Eur J Obstet
731	<i>Gynecol Reprod Biol</i> 2019; 237 :48–56.
732	Unler GK, Gokturk HS, Toprak E, Erinanc OH, Korkmaz H. Does the Presence of Endometrial
733	Polyp Predict Colorectal Polyp? Am J Med Sci 2016;351:129–132.

36

- Vieira MDC, Vitagliano A, Rossette MC, Neto LC de A, Gallo A, Sardo ADS. Endometrial 734 735 Polyps: Update Overview on Etiology, Diagnosis, Natural History and Treatment. CEOG 2022;49:232. IMR Press. 736 737 Vitale SG, Haimovich S, Laganà AS, Alonso L, Di Spiezio Sardo A, Carugno J, From the Global Community of Hysteroscopy Guidelines Committee. Endometrial polyps. An 738 739 evidence-based diagnosis and management guide. Eur J Obstet Gynecol Reprod Biol 740 2021;**260**:70–77. 741 Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010;38:e164. 742 743 Watanabe K, Taskesen E, Bochoven A van, Posthuma D. Functional mapping and annotation 744 of genetic associations with FUMA. Nat Commun 2017;8:1826. 745 Wu L, Wang Y, Liu Y, Yu S, Xie H, Shi X, Qin S, Ma F, Tan TZ, Thiery JP, et al. A central
- role for TRPS1 in the control of cell cycle and cancer development. *Oncotarget*2014;5:7677–7690.
- Yi SE, LaPolt PS, Yoon BS, Chen JY, Lu JK, Lyons KM. The type I BMP receptor BmprIB is
 essential for female reproductive function. *Proc Natl Acad Sci U S A* 2001;**98**:7994–
 750 7999.
- Zhang Y-N, Zhang Y-S, Yu Q, Guo Z-Z, Ma J-L, Yan L. Higher Prevalence of Endometrial
 Polyps in Infertile Patients with Endometriosis. *Gynecol Obstet Invest* 2018;83:558–
 563.
- 754
- 755
- 756

758	Supple	ementary materials:				
759	Supplementary figure 1: Genome-wide gene association analysis of our GWAS dataset					
760	using 'Multi-marker Analysis of GenoMic Annotation (MAGMA) wherein input SNPs					
761	were r	napped to 18895 protein-coding genes. On the Manhattan plot, the y-axis represents				
762	-log10	(P-values) for the association of variants identified in polyps of the female genital tract.				
763	The ho	prizontal red dashed line represents the genome-wide significance threshold (P < 5 \times				
764	10-8)	and prioritised genes for each locus are shown. Genes associated with exonic missense				
765	variant	as are denoted in red text.				
766						
767	Supple	ementary Tables:				
768	ST 1	Genes mapped by expression quantitative trait loci (eQTL) and Chromatin interactions				
769		by Functional Mapping and Annotation of Genome-Wide Association Studies (FUMA				
770		GWAS)				
771	ST 2	Results of the Multi-marker Analysis of GenoMic Annotation (MAGMA) gene-based				
772		analysis				
773	ST 3	Results of the GWAS catalogue lookup				
774	ST 4	Look-up of the 10 lead variants in endometrial cancer summary statistics				
775		(https://pubmed.ncbi.nlm.nih.gov/31040137/)				
776	ST 5	Genetic correlation between female genital tract polyps and other traits				
777	ST 6	Phenotypes associated with Polyps of the female genital tract				
778	ST 7	Results of survival analysis lookup in FinnGen data				
779						
780						
781						